GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting

GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting

ID: 477245

(firmenpresse) - ATLANTA, GA -- (Marketwired) -- 06/13/16 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Chief Scientific Officer, Dr. Harriet Robinson, will give an oral presentation at the American Society for Virology's 35th Annual Meeting, to be held at Virginia Polytechnic Institute and State University in Blacksburg, Virginia on June 18-22, 2016.

Dr. Robinson's presentation, entitled "Development of a Zika Vaccine," will be delivered at 2:00pm on Tuesday, June 21, 2016 during the late-breaking Zika workshop at the conference. Further details from Dr. Robinson's talk will be released immediately following her presentation.

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company's development programs are focused on vaccines against Zika Virus, HIV, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa). GeoVax also recently began programs to evaluate the use of its MVA-VLP platform in cancer immunotherapy and in developing a vaccine to treat chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the individual receiving the vaccine. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.



Robert T. McNally, Ph.D.
GeoVax Labs, Inc.

678-384-7220



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Justin Barnes, Health IT Industry Leader, Joins iHealth Lifeline Biotechnologies Updates Current Matters
Bereitgestellt von Benutzer: Marketwired
Datum: 13.06.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 477245
Anzahl Zeichen: 5631

contact information:
Town:

ATLANTA, GA



Kategorie:

Alternative



Diese Pressemitteilung wurde bisher 318 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von

GeoVax, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

GeoVax HIV Clinical Trials Update ...

ATLANTA, GA -- (Marketwired) -- 11/15/17 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced that the HIV Vaccine Trials Network (HVTN) has closed enrollment for the phase 1 human clinical trial eva ...

Alle Meldungen von GeoVax, Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z